Based on a published REST signature consisting of 24 downstream targets of REST14, we previously discovered that REST activity predicted drug sensitivity in neuroblastoma cell lines and was a prognostic biomarker for neuroblastoma tumor stage15. This evidence concerns the gene REST and neuroblastoma.